Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016

Date: July 27, 2016
Pages: 137
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PE924B999EBEN
Leaflet:

Download PDF Leaflet

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016’, provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)
  • The report reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Post-Traumatic Stress Disorder (PTSD) therapeutics and enlists all their major and minor projects
  • The report assesses Post-Traumatic Stress Disorder (PTSD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD)
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Post-Traumatic Stress Disorder (PTSD) Overview
Therapeutics Development
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Overview
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Development by Companies
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Investigation by Universities/Institutes
Post-Traumatic Stress Disorder (PTSD) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Post-Traumatic Stress Disorder (PTSD) - Products under Development by Companies
Post-Traumatic Stress Disorder (PTSD) - Products under Investigation by Universities/Institutes
Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
Azevan Pharmaceuticals, Inc.
Bionomics Limited
Catalyst Pharmaceuticals, Inc.
Eli Lilly and Company
Humanetics Corporation
Intra-Cellular Therapies, Inc.
INVENT Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc.
Neuralstem, Inc.
NeuroNascent, Inc.
Omeros Corporation
Otsuka Holdings Co., Ltd.
Polleo Pharma Limited
Pragma Therapeutics
Synchroneuron Inc.
Tonix Pharmaceuticals Holding Corp.
TRImaran Pharma, Inc.
Turing Pharmaceuticals AG
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acamprosate calcium SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-71743 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-3506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brexpiprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPP-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ganaxolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-9001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IC-87201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-170 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITI-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDAC-0001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketamine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
modafinil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NNI-351 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSI-189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGT-117 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rycal - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-246 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URB-694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZL-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
Featured News & Press Releases
Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder
Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases
Jun 03, 2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention
May 31, 2016: Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the American Society of Clinical Psychopharmacology 2016 Annual Meeting
May 26, 2016: Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting
May 19, 2016: Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting
Dec 23, 2015: Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder
Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210
Nov 23, 2015: The SEVEN4PTSD consortium led by PRAGMA Therapeutics awarded 2015 French ANR grant to further advance its mGlu7 program for Post-Traumatic Stress Disorder
Oct 29, 2015: Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation
Aug 18, 2015: Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium
May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR
May 15, 2015: Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry
Jan 15, 2015: Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2016
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc., H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Limited, H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Company, H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Humanetics Corporation, H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem, Inc., H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent, Inc., H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corporation, H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Polleo Pharma Limited, H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics, H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc., H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by TRImaran Pharma, Inc., H2 2016
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Turing Pharmaceuticals AG , H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2016
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects (Contd..1), H2 2016
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2016
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
Azevan Pharmaceuticals, Inc.
Bionomics Limited
Catalyst Pharmaceuticals, Inc.
Eli Lilly and Company
Humanetics Corporation
Intra-Cellular Therapies, Inc.
INVENT Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc.
Neuralstem, Inc.
NeuroNascent, Inc.
Omeros Corporation
Otsuka Holdings Co., Ltd.
Polleo Pharma Limited
Pragma Therapeutics
Synchroneuron Inc.
Tonix Pharmaceuticals Holding Corp.
TRImaran Pharma, Inc.
Turing Pharmaceuticals AG
Skip to top


Ask Your Question

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: